Protein kinase C isoform expression in chronic lymphocytic leukemia: A potential target for therapy?

Leukemia and Lymphoma

Volumn 54, Issue 10, 2013, Pages 2098-2099

  Best, O Giles ^a   Tam, Constantine ^b,c  

^a ROYAL NORTH SHORE HOSPITAL   (Australia)

^b ST VINCENT S HOSPITAL   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

7 HYDROXYSTAUROSPORINE; FLAVOPIRIDOL; IBRUTINIB; IDELALISIB; ISOENZYME; MIDOSTAURIN; PROTEIN KINASE C; PROTEIN KINASE ZAP 70;

CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL (TOPIC); GENE OVEREXPRESSION; HUMAN; NOTE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL;

GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; PROTEIN KINASE C;

EID: 84884497591     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2013.779692     Document Type: Note

References (19)

1. Mellor H Parker PJ. The extended protein kinase C superfamily. Biochem J 1998; 332: 281-292.
2. Alkan S, Huang Q, Ergin M, et al. Survival role of protein kinase C (PKC) in chronic lymphocytic leukemia and determination of isoform expression pattern and genes altered by PKC inhibition. Am J Hematol 2005; 79: 97-106.
3. Barragan M, de Frias M, Iglesias-Serret D, et al. Regulation of Akt/PKB by phosphatidylinositol 3-kinase-dependent and -independent pathways in B-cell chronic lymphocytic leukemia cells: Role of protein kinase C{beta}. J Leukoc Biol 2006; 80: 1473-1479.
4. Kabir NN, Rönnstrand L, Kazi JU. Protein kinase C expression is deregulated in chronic lymphocytic leukemia. Leuk Lymphoma 2013; 54: 2288-2290.
5. Abrams ST, Lakum T, Lin K, et al. B-cell receptor signaling in chronic lymphocytic leukemia cells is regulated by overexpressed active protein kinase CbetaII. Blood 2007; 109: 1193-1201.
6. Ringshausen I, Schneller F, Bogner C, et al. Constitutively activated phosphatidylinositol-3 kinase (PI-3K) is involved in the defect of apoptosis in B-CLL: Association with protein kinase Cdelta. Blood 2002; 100: 3741-3748.
7. Perez-Chacon G, Vargas JA, Jorda J, et al. CD5 provides viability signals to B cells from a subset of B-CLL patients by a mechanism that involves PKC. Leuk Res 2007; 31: 183-193.
8. Hubmann R, Duchler M, Schnabl S, et al. N OTCH2 links protein kinase C delta to the expression of CD23 in chronic lymphocytic leukaemia (CLL) cells. Br J Haematol 2010; 148: 868-878.
9. zum Buschenfelde CM, Wagner M, Lutzny G, et al. Recruitment of PKC-betaII to lipid rafts mediates apoptosis-resistance in chronic lymphocytic leukemia expressing ZAP-70. Leukemia 2010; 24: 141-152.
10. Lutzny G, Kocher T, Schmidt-Supprian M, et al. Protein kinase C-beta-dependent activation of NF-kappaB in stromal cells is indispensable for the survival of chronic lymphocytic leukemia B cells in vivo. Cancer Cell 2013; 23: 77-92.
11. Furman RR, Byrd JC, Brown JR, et al. CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110{delta}, demonstrates clinical activity and pharmacodynamic effects in patients with relapsed or refractory chronic lymphocytic leukemia. Blood 2010; 116(Suppl. 1): Abstract 55.
12. Burger JA, O'B rien S, Fowler N, et al. The Bruton's tyrosine kinase inhibitor, PCI- 32765, is well tolerated and demonstrates promising clinical activity in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL): An update on ongoing phase 1 studies. Blood 2010; 116(Suppl. 1): Abstract 57.
13. Byrd JC, Shinn C, Willis CR, et al. UCN-01 induces cytotoxicity toward human CLL cells through a p53-independent mechanism. Exp Hematol 2001; 29: 703-708.
14. Ganeshaguru K, Wickremasinghe RG, Jones DT, et al. Actions of the selective protein kinase C inhibitor PKC412 on B-chronic lymphocytic leukemia cells in vitro. Haematologica 2002; 87: 167-176.
15. Sato S, Fujita N, Tsuruo T. Interference with PDK1-Akt survival signaling pathway by UCN-01 (7-hydroxystaurosporine). Oncogene 2002; 21: 1727-1738.
16. Virchis A, Ganeshaguru K, Hart S, et al. A novel treatment approach for low grade lymphoproliferative disorders using PKC412 (CGP41251), an inhibitor of protein kinase C. Hematol J 2002; 3: 131-136.
17. Sedlacek HH. Mechanisms of action of fl avopiridol. Crit Rev Oncol Hematol 2001; 38: 139-170.
18. Ringshausen I, Oelsner M, Weick K, et al. Mechanisms of apoptosis-induction by rottlerin: Therapeutic implications for B-CLL. Leukemia 2006; 20: 514-520.
19. Forsyth CJ, Gomez D, Eliadis P, et al. Enzastaurin in patients with non-Hodgkin lymphomas: A multicenter, open-label, screening study. Blood 2009; 114(Suppl. 1): Abstract 3719.